Antidepressant drugs for beta amyloid-induced depression: A new standpoint?

Progress in Neuro-psychopharmacology & Biological Psychiatry
Stefania SchiavoneMaria Grazia Morgese

Abstract

Mounting evidence suggests that depression represents a risk factor and an early manifestation of Alzheimer's disease (AD). Neuropsychiatric symptoms may derive from neurobiological changes in specific brain areas and may be considered prodromal of dementia. We have previously reported the depressive-like profile in rats receiving a single intracerebroventricular injection of soluble amyloid beta protein (ßA). Here, we verified the effect of different classes of antidepressants on the ßA-induced depressive behavior and on cortical monoamine levels. To these purposes, the forced swimming test was performed and cortical levels of serotonin (5-HT) and noradrenaline (NA) were quantified by high performance liquid chromatography (HPLC). We found that acute fluoxetine (20mg/kg, s.c.), reboxetine (10mg/kg, s.c.), and ketamine (15mg/kg, i.p.) significantly reduced the immobility in ßA-treated rats compared to controls. Fluoxetine and reboxetine reversed 5-HT reduction, while βA-induced NA increase was further enhanced by all treatments. Treatments with fluoxetine, reboxetine and ketamine were able to revert soluble ßA-induced decrease of cortical BDNF levels, while only fluoxetine and ketamine, but not reboxetine, had the same effects ...Continue Reading

References

Mar 1, 2016·Molecular Neurobiology·Maria Grazia MorgeseVincenzo Cuomo

❮ Previous
Next ❯

Citations

Jun 29, 2018·International Journal of Geriatric Psychiatry·Mitzi M GonzalesUNKNOWN Alzheimer's Disease Neuroimaging Initiative
Nov 6, 2018·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Dan ChengYi Lu
Apr 2, 2020·Frontiers in Pharmacology·Christoph Linnemann, Undine E Lang
Nov 7, 2019·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Stefania SchiavoneMaria Grazia Morgese
Apr 21, 2020·Anesthesiology Research and Practice·Abby PribishArun Kalava
Jun 4, 2019·Frontiers in Pharmacology·Maria Grazia Morgese, Luigia Trabace
Jul 22, 2018·Biochemical Pharmacology·Maria BoveLuigia Trabace
May 1, 2021·Pharmaceuticals·Maria Grazia MorgeseLuigia Trabace
Oct 27, 2017·Psychiatry Research·Satoko IshijimaHeii Arai
Jun 3, 2021·Biomolecules·Maria Grazia MorgesePaolo Tucci

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.